These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34566421)

  • 1. WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M.
    Henning P; Movérare-Skrtic S; Westerlund A; Chaves de Souza PP; Floriano-Marcelino T; Nilsson KH; El Shahawy M; Ohlsson C; Lerner UH
    J Inflamm Res; 2021; 14():4723-4741. PubMed ID: 34566421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.
    de Souza PPC; Henning P; Lerner UH
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor.
    Persson E; Souza PPC; Floriano-Marcelino T; Conaway HH; Henning P; Lerner UH
    Front Immunol; 2019; 10():1164. PubMed ID: 31191537
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
    Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
    J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.
    Sims NA; Lévesque JP
    Curr Osteoporos Rep; 2024 Feb; 22(1):80-95. PubMed ID: 38198032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone.
    Richards CD; Langdon C; Deschamps P; Pennica D; Shaughnessy SG
    Cytokine; 2000 Jun; 12(6):613-21. PubMed ID: 10843736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
    Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
    J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncostatin M receptor regulates osteoblast differentiation via extracellular signal-regulated kinase/autophagy signaling.
    Zhou J; Yang J; Dong Y; Shi Y; Zhu E; Yuan H; Li X; Wang B
    Stem Cell Res Ther; 2022 Jun; 13(1):278. PubMed ID: 35765036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.
    Walker EC; McGregor NE; Poulton IJ; Solano M; Pompolo S; Fernandes TJ; Constable MJ; Nicholson GC; Zhang JG; Nicola NA; Gillespie MT; Martin TJ; Sims NA
    J Clin Invest; 2010 Feb; 120(2):582-92. PubMed ID: 20051625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
    Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
    Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
    Malaval L; Liu F; Vernallis AB; Aubin JE
    J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
    Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
    J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.
    Guihard P; Danger Y; Brounais B; David E; Brion R; Delecrin J; Richards CD; Chevalier S; Rédini F; Heymann D; Gascan H; Blanchard F
    Stem Cells; 2012 Apr; 30(4):762-72. PubMed ID: 22267310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.
    Kokkotis G; Filidou E; Tarapatzi G; Spathakis M; Kandilogiannakis L; Dovrolis N; Arvanitidis K; Drygiannakis I; Valatas V; Vradelis S; Manolopoulos VG; Paspaliaris V; Kolios G; Bamias G
    Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38717842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicity.
    Moidunny S; Matos M; Wesseling E; Banerjee S; Volsky DJ; Cunha RA; Agostinho P; Boddeke HW; Roy S
    J Neuroinflammation; 2016 Jun; 13(1):144. PubMed ID: 27287400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption.
    Jay PR; Centrella M; Lorenzo J; Bruce AG; Horowitz MC
    Endocrinology; 1996 Apr; 137(4):1151-8. PubMed ID: 8625883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.